Advancing ALS research: public-private partnerships to accelerate drug and biomarker development

Alessio Travaglia; Shubhangi Lal; Sri Ramulu Pullagura

doi:10.1016/j.tins.2024.10.008

Advancing ALS research: public-private partnerships to accelerate drug and biomarker development

Trends Neurosci. 2024 Nov 21:S0166-2236(24)00205-4. doi: 10.1016/j.tins.2024.10.008. Online ahead of print.

Authors

Alessio Travaglia¹, Shubhangi Lal², Sri Ramulu Pullagura²

Affiliations

¹ Foundation for the National Institutes of Health (FNIH), North Bethesda, MD, USA. Electronic address: [email protected].
² Foundation for the National Institutes of Health (FNIH), North Bethesda, MD, USA.

PMID: 39578133
DOI: 10.1016/j.tins.2024.10.008

Abstract

Developing effective treatments for amyotrophic lateral sclerosis (ALS) has been hindered by both the complexity of the disease and decentralized research efforts. By fostering collaboration, standardization, and inclusivity, the Accelerating Medicines Partnership® (AMP®) ALS initiative aims to lay the foundation for future discoveries in ALS biomarkers and treatments.

Keywords: FNIH; amyotrophic lateral sclerosis; collaboration; patients.